Background illustration for clinical trials search

Paid Clinical Trials Buffalo

Discover 779 paid clinical trials in Buffalo, New York. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

for
Endometrial Cancer
Location: Toronto, Barrie, London, Pittsburgh PA, Windsor,
Sponsor: Merck Sharp & Dohme LLC

Sex: Female

Age: 18+

Code: NCT06952504

Phase 3, Recruiting

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

for
Breast Neoplasms
Location: Toronto, Pittsburgh PA, York PA, Winchester VA,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07060807

Phase 3, Recruiting

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

for
CRC (Colorectal Cancer)
Location: Toronto, Pittsburgh PA, Morgantown WV, York PA,
Sponsor: Incyte Corporation

Sex: All

Age: 18+

Code: NCT07284849

Phase 3, Recruiting

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

for
Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic,
Location: Toronto, Oshawa, Mentor OH, Orange OH, Cleveland OH,
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT07144280

Phase 3, Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

for
Metastatic Head-and-neck Squamous-cell Carcinoma,
Location: Toronto, Pittsburgh PA, Baltimore MD, Philadelphia PA,
Sponsor: AVEO Pharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT06064877

Phase 3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

for
Multiple Myeloma
Location: Toronto, Cleveland OH, Allentown PA, Ottawa,
Sponsor: European Myeloma Network B.V.

Sex: All

Age: 18+

Code: NCT05243797

Phase 3, Recruiting

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

for
Relapsed/Refractory Multiple Myeloma
Location: Toronto, Hackensack NJ, New York NY, Columbus OH,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT04973605

Phase 1, Phase 2, Recruiting

Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

for
Recurrent Prostate Cancer
Location: Toronto, New York NY
Sponsor: SpectraCure AB

Sex: Male

Age: 18+

Code: NCT03067051

Phase 1, Phase 2, Recruiting

A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

for
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Location: Toronto, Detroit MI, Baltimore MD, Washington D.C. DC,
Sponsor: Nuvalent Inc.

Sex: All

Age: 18+

Code: NCT06521554

Phase 1, Recruiting

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

for
Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
Location: Toronto, Sellersville PA, Fairfax VA, New York NY,
Sponsor: Nuvalent Inc.

Sex: All

Age: 18+

Code: NCT06765109

Phase 3, Recruiting

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

for
Advanced Solid Tumor
Location: Toronto, New York NY, New Hyde Park NY, New Haven CT,
Sponsor: Debiopharm International SA

Sex: All

Age: 12+

Code: NCT04855656

Phase 1, Recruiting

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

for
Solid Tumors
Location: Toronto, Philadelphia PA, Fairfax VA,
Sponsor: ORIC Pharmaceuticals

Sex: All

Age: 18+

Code: NCT05315700

Phase 1, Phase 2, Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

for
Biliary Tract Cancer
Location: Toronto, New York NY, Richmond VA, Louisville KY,
Sponsor: Jazz Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06282575

Phase 3, Recruiting

Pan Tumor Rollover Study

for
Cancer
Location: Toronto, Lancaster PA, Columbus OH, Mineola NY,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT03899155

Phase 2, Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

for
Advanced Non-Small Cell Lung Cancer,
Location: Toronto, Cleveland OH, Pittsburgh PA, Massillon OH,
Sponsor: Mirati Therapeutics Inc.

Sex: All

Age: 18+

Code: NCT04613596

Phase 2, Phase 3, Recruiting

A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

for
Cervical Cancer
Location: Toronto, Cleveland OH, Pittsburgh PA, Akron OH,
Sponsor: GOG Foundation

Sex: Female

Age: 18+

Code: NCT04831580

Recruiting

DALY II USA/ MB-CART2019.1 for DLBCL

for
Refractory Diffuse Large B Cell Lymphoma (DLBCL),
Location: Toronto, Pittsburgh PA, Ann Arbor MI, Baltimore MD,
Sponsor: Miltenyi Biomedicine GmbH

Sex: All

Age: 18+

Code: NCT04792489

Phase 2, Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

for
Advanced or Metastatic Solid Tumors
Location: Toronto, New York NY, New Haven CT, Grand Rapids MI,
Sponsor: Day One Biopharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT06752681

Phase 1, Recruiting

Study of Olverembatinib (HQP1351) in Patients With CML-CP

for
Chronic Myeloid Leukemia, CML, CML, Chronic Phase
Location: Toronto, Rochester NY, Pittsburgh PA, Detroit MI,
Sponsor: Ascentage Pharma Group Inc.

Sex: All

Age: 18+

Code: NCT06423911

Phase 3, Recruiting

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

for
IC-MPGN
Location: Toronto, Etobicoke, London, Philadelphia PA,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 12 - 60

Code: NCT05755386

Phase 3, Recruiting